Key Developments: Aceto Corp (ACET.O)
11.80USD
12:02pm EDT
$-0.14 (-1.17%)
$11.94
$11.83
$11.93
$11.70
25,182
105,170
$12.08
$8.02
Latest Key Developments (Source: Significant Developments)
Aceto Corp Declares Quarterly Cash Dividend
Aceto Corp announced that its Board of Directors has declared a regular quarterly dividend of $0.055 per common share. This quarterly cash dividend will be distributed on June 25, 2013 to shareholders of record as of June 14, 2013. Full Article
Aceto Corp Declares Quarterly Cash Dividend
Aceto Corp announced that its Board of Directors has declared a regular quarterly dividend of $0.055 per common share. This quarterly cash dividend will be distributed on March 26, 2013 to shareholders of record as of March 15, 2013. Full Article
Aceto Corp's Rising Pharmaceuticals Inc. Launches Generic Version Of Grifulvin V
Aceto Corp announced that Rising Pharmaceuticals Inc., finished dosage form generics subsidiary, launched the generic version of the 500 mg strength (microsize) of Griseofulvin Tablets USP, an FDA approved generic version of Valeant Pharmaceutical's Grifulvin V. The launch of the 500 mg strength of Griseofulvin tablets USP follows the previously announced launch of the generic version of the 125mg and 250mg strengths of Ultramicrosize Griseofulvin tablets USP by Rising Pharmaceuticals in November 2012. Full Article
Aceto Corp Declares Regular Quarterly Dividend
Aceto Corp announced that its Board of Directors has declared a regular quarterly dividend of $0.055 per common share. This quarterly cash dividend will be distributed on December 28, 2012 to shareholders of record as of December 17, 2012. Full Article
Aceto Corp's Rising Pharmaceuticals Inc Announces To Launch Generic Version Of Cleocin Pediatric
Aceto Corp's Rising Pharmaceuticals Inc. announced that it has launched the generic version of the 75mg/5mL strength of Clindamycin Palmitate Hydrochloride for Oral Solution, USP (Pediatric), an FDA approved generic version of Pfizer Inc.'s Cleocin Pediatric. According to IMS Health data, U.S. market sales for Clindamycin Palmitate Hydrochloride, which is an antibiotic that is used to treat serious infections caused by bacteria, were approximately $59 million for the twelve months ended June 30, 2012. Full Article
Aceto Corp's Rising Pharmaceuticals Inc Announces to Launch First Generic Version of Gris-PEG
Aceto Corp's Rising Pharmaceuticals Inc announced that it will launch the first generic version of the 125mg and 250mg strengths of Ultramicrosize Griseofulvin Tablets USP, an FDA approved generic version of PEDiNOL Pharmacal, Inc.'s Gris-PEG. According to IMS Health data, U.S. market sales for Ultramicrosize Griseofulvin Tablets, which is an antifungal antibiotic that fights infections caused by fungus, were approximately $16.7 million for the twelve months ended June 30, 2012. Full Article
Aceto Corp Outlines Chief Executive Officer Succession Plan
Aceto Corp announced that as part of the Company's Management Succession Plan, effective January 2, 2013 Albert Eilender, Chairman and Chief Executive Officer will step down from his position as Chief Executive Officer while retaining his duties as Chairman of the Board. The Board of Directors elected Salvatore Guccione, currently President and Chief Operating Officer and member of the Board, to succeed him as Chief Executive Officer, effective January 2, 2013. Full Article
Aceto Corp Declares Regular Quarterly Dividend Of $0.055 Per Share
Aceto Corp announced that its Board of Directors declared a regular quarterly dividend of $0.055 per common share. This quarterly cash dividend will be distributed on September 28, 2012 to shareholders of record as of September 17, 2012. This quarterly dividend represents an increase of 10% on an annualized basis. Full Article
Aceto Corporation Declares Regular Semi-Annual Dividend
Aceto Corporation announced that the Board of Directors has declared a regular semi-annual dividend of $0.10 per common share. This semi-annual cash dividend will be distributed on June 22, 2012 to shareholders of record as of June 11, 2012. Full Article
Aceto Corporation Announces Rising Pharmaceuticals Subsidiary Launches Generic Version of Ancobon Capsules And Aralen Tablets
Aceto Corporation announced that Rising Pharmaceuticals Inc., its generic finished dosage form subsidiary, has launched the 250 mg and 500 mg strengths of Flucytosine Capsules, the first approved generic version of Valeant Pharmaceuticals International's Ancobon Capsules, and 500 mg strength of Chloroquine Phosphate Tablets, an approved generic version of Sanofi Aventis US's Aralen Tablets, following the U.S. Food and Drug Administration (FDA) approval of both Abbreviated New Drug Applications (ANDA's). Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
